靶向线粒体抗神经退行性疾病新型药物研究进展

线粒体是广泛存在于神经元细胞中的细胞器，它既能通过氧化磷酸化作用为各种生命活动提供能量，也参与了如钙稳态和细胞凋亡等多种病理生理性活动的调节。大量研究证明线粒体功能障碍在帕金森病、阿尔茨海默病等神经退行性疾病的早期发生过程中发挥重要作用。探索线粒体在该类疾病发生过程中的变化，对认识神经退行性疾病的发病机制，开发新型神经保护药物具有重要意义。事实上，一些线粒体靶向性药物已用于神经退行性疾病的临床治疗或正处于不同研究阶段。本文通过对有关线粒体在神经退行性疾病中相关证据的讨论，综述线粒体靶向性神经保护剂的研究进展，论证其作为神经退行性疾病治疗药物的可行性。

Advances in novel anti-neurodegenerative diseases drugs targeting mitochondria

Mitochondria,the major organelle in neurons,which provides energy via oxidative phosphorylation for all kinds of metabolic activities,is involved in many pathophysiological processes,such as calcium homeostasis and apoptosis. Increasing evi?dence has indicated that mitochondrial dysfunction displays a significant role in the early stage of neurodegenerative disorders like Par?kinson′s disease(PD)and Alzheimer′s disease(AD). Therefore,studies which focus on mitochondrial dysfunction under these patho?logical conditions contribute to understanding the pathogenesis of neurodegenerative disorder and discovering new neuroprotective drugs. Actually,various mitochondria-targeting agents have been tried in clinic or under different investigational phases against neuro?degenerative disorders. This review discusses the evidence on mitochondrial impairments during neurodegenerative diseases and the advances in mitochondria-targeting agents as a potential alternative drug strategy for effective management of neurodegenerative diseases.